[News in cystic fibrosis]

Area of Science:

• Medical Genetics
• Pulmonology
• Pharmacology

Background:

• Improved cystic fibrosis (CF) treatments have significantly increased life expectancy, leading to a growing adult patient population.
• Neonatal screening for CF, established in 2003, utilizes immunoreactive trypsinogen levels and mutation analysis, detecting approximately 96% of cases.
• The incidence of CF is now reported as 1/5359 live births, lower than the previously accepted 1/2500.

Discussion:

• Despite screening advancements, false negatives are possible, necessitating sweat tests for symptomatic children.
• Current treatments manage CF symptoms, but novel CFTR modulators aim to correct the underlying protein defect.
• Ivacaftor, a CFTR potentiator, is available for G551D mutation carriers; CFTR correctors are in development for the common DF508 mutation.

Key Insights:

• Neonatal screening for cystic fibrosis has a lower incidence than previously estimated.
• New CFTR modulator therapies represent a paradigm shift, targeting the root cause of CF.
• The development of CFTR correctors holds promise for patients with the most prevalent DF508 mutation.

Outlook:

• Continued development of CFTR modulators is expected to further improve treatment efficacy and patient outcomes.
• Personalized medicine approaches will likely become more prominent in managing cystic fibrosis.
• Long-term studies are needed to fully assess the impact of CFTR modulators on life expectancy and quality of life.